LABD: Breakout Setup Above $6.68!LABD is forming a bullish breakout setup with an entry point at $6.68. Here are the trade parameters:
Entry: $6.68 (yellow line, breakout level).
Stop Loss (SL): $6.47 (below support zone).
Take Profit Targets:
Target 1 (T1): $7.11 (first resistance level).
Target 2 (T2): $7.56 (next resistance le
Key stats
About Direxion Daily S&P Biotech Bear 3X Shares
Home page
Inception date
May 28, 2015
Structure
Open-Ended Fund
Replication method
Synthetic
Dividend treatment
Distributes
Distribution tax treatment
Ordinary income
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Rafferty Asset Management LLC
Distributor
Foreside Fund Services LLC
LABD is a daily leveraged inverse (-3x) bet on an equal-weighted index of US biotech stocks. The vast majority of the fund's exposure is to biotechnology and medical research but also captures significant exposure to pharmaceuticals as well. As a leveraged product, the fund is not a buy-and-hold investment. It gets its leverage exposure through a through a portfolio of swaps that gets rebalanced at the end of each trading day. Because of that, the fund's return for periods longer than a day becomes path-dependent and is likely to be different from -3x the return of the index for the same period. This makes LABD suitable primarily for short-term traders. Over time, compounding effects can lead to profound differences in expected returns relative to the index.
Classification
What's in the fund
Exposure type
Cash
Bonds, Cash & Other100.00%
Cash100.00%
Top 10 holdings
Strong bullish case for $LABDCan see this at $15.00 given that is where most shares are currently held, according to FRVP; this means there will likely be little downwards price pressure until then. Biotech is generally bearish outside of select, short-lived bull runs - this, in my opinion, creates an opportunity for sentiment
Direxion Daily S&P Biotech Bear 3X Shares (LABD)On daily chart, LABD is trading in an uptrend, and by Friday’s session, LABD has broken major resistance that lies on 29.19$, and the confirmation of that breakout, will trigger LABD witness further rises near to 31.72 – 34.20 – 41.40 – 42.71 om short term basis.
Stop loss will lies below 25.66$(las
LABD 3X BEAR BIOTECH LONG DAYTRADEAs shown on the 15-minute chart, LABD is bouncing between stardard deviations of the VWAP in a 6% price range
fluctuation day to day. At the upper end it is reversing at the POC of the volume profile confluent with one
standard deviation above VWAP while at the bottom it is bouncing from the
LABD false breakdownXBI has been super weak lately, and in our earlier decline lead the way down. On the whole I think its a garbage sector RN with the amount of uncertainty in the market and the fed raising rates. The chop it's experienced in the past few months is textbook bearmarket. No one wants it, but everyone's
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related funds
Frequently Asked Questions
An exchange-traded fund (ETF) is a collection of assets (stocks, bonds, commodities, etc.) that track an underlying index and can be bought on an exchange like individual stocks.
LABD trades at 7.13 USD today, its price has fallen −5.74% in the past 24 hours. Track more dynamics on LABD price chart.
LABD net asset value is 7.14 today — it's fallen 10.15% over the past month. NAV represents the total value of the fund's assets less liabilities and serves as a gauge of the fund's performance.
LABD assets under management is 53.06 M USD. AUM is an important metric as it reflects the fund's size and can serve as a gauge of how successful the fund is in attracting investors, which, in its turn, can influence decision-making.
LABD price has fallen by −24.07% over the last month, and its yearly performance shows a 1.42% increase. See more dynamics on LABD price chart.
NAV returns, another gauge of an ETF dynamics, have risen by −10.15% over the last month, have fallen by −10.15% over the last month, showed a −7.50% decrease in three-month performance and has increased by 5.55% in a year.
NAV returns, another gauge of an ETF dynamics, have risen by −10.15% over the last month, have fallen by −10.15% over the last month, showed a −7.50% decrease in three-month performance and has increased by 5.55% in a year.
LABD fund flows account for −106.94 M USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Since ETFs work like an individual stock, they can be bought and sold on exchanges (e.g. NASDAQ, NYSE, EURONEXT). As it happens with stocks, you need to select a brokerage to access trading. Explore our list of available brokers to find the one to help execute your strategies. Don't forget to do your research before getting to trading. Explore ETFs metrics in our ETF screener to find a reliable opportunity.
LABD invests in cash. See more details in our Analysis section.
LABD expense ratio is 1.07%. It's an important metric for helping traders understand the fund's operating costs relative to assets and how expensive it would be to hold the fund.
LABD is an inverse fund, meaning it's structured to generate returns opposite to the trends of the underlying index or assets.
In some ways, ETFs are safe investments, but in a broader sense, they're not safer than any other asset, so it's crucial to analyze a fund before investing. But if your research gives a vague answer, you can always refer to technical analysis.
Today, LABD technical analysis shows the strong sell rating and its 1-week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1-month rating LABD shows the strong sell signal. See more of LABD technicals for a more comprehensive analysis.
Today, LABD technical analysis shows the strong sell rating and its 1-week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1-month rating LABD shows the strong sell signal. See more of LABD technicals for a more comprehensive analysis.
Yes, LABD pays dividends to its holders with the dividend yield of 4.33%.
LABD trades at a premium (0.08%).
Premium/discount to NAV expresses the difference between the ETF’s price and its NAV value. A positive percentage indicates a premium, meaning the ETF trades at a higher price than the calculated NAV. Conversely, a negative percentage indicates a discount, suggesting the ETF trades at a lower price than NAV.
Premium/discount to NAV expresses the difference between the ETF’s price and its NAV value. A positive percentage indicates a premium, meaning the ETF trades at a higher price than the calculated NAV. Conversely, a negative percentage indicates a discount, suggesting the ETF trades at a lower price than NAV.
LABD shares are issued by Rafferty Asset Management LLC
LABD follows the S&P Biotechnology Select Industry. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
The fund started trading on May 28, 2015.
The fund's management style is passive, meaning it's aiming to replicate the performance of the underlying index by holding assets in the same proportions as the index. The goal is to match the index's returns.